CalRx® Naloxone delivers significant cost savings to California 

Since its launch in May 2024, CalRx®-branded naloxone has become the primary product supplied for California’s Naloxone Distribution Project (NDP), which provides lifesaving medication to harm reduction groups, schools, emergency responders, and more at no cost to qualifying organizations.  

By securing 4 mg CalRx naloxone nasal spray from the manufacturer, Amneal Pharmaceuticals, at just $24 per twin-pack, the CalRx® Naloxone Access Initiative has saved California several million dollars to date, as highlighted by the monthly CalRx® Naloxone State Savings Tracker:  

About this data:

• CalRx-branded naloxone nasal spray became available in California in May 2024.
• Amneal Pharmaceuticals provides monthly sales data for CalRx/Amneal naloxone, while data on NDP purchases include units from the non-CalRx®-branded supplier and CalRx®-branded/Amneal® branded units.
• State savings are calculated by comparing the $24 cost per unit of CalRx® 4 mg naloxone nasal spray to the cost of the historical supplier.
• Cumulative savings reflect the total sum of monthly state savings since the launch of the CalRx® Naloxone Access Initiative.
• When accounting for the CalRx program’s lower price and the fact that CalRx® entry pushed down other suppliers’ prices, CalRx naloxone has already saved California over $21.7 million. By the end of State Fiscal Year 2024-25, these savings are projected to be $40 million.